UBS AM
EGRX

UBS AM’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

UBS AM’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,255
Closed -$206K – 2702
2023
Q2 		$206K Hold
7,255
– – ﹤0.01% 2565
2023
Q1 		$206K Sell
7,255
-544
-7% -$16.1K ﹤0.01% 2565
2022
Q4 		$228K Hold
7,799
– – ﹤0.01% 2411
2022
Q3 		$206K Sell
7,799
-5,143
-40% -$189K ﹤0.01% 2604
2022
Q2 		$575K Sell
12,942
-484
-4% -$22.2K ﹤0.01% 2254
2022
Q1 		$664K Buy
13,426
+1,443
+12% +$69.3K ﹤0.01% 2350
2021
Q4 		$610K Buy
11,983
+211
+2% +$10.9K ﹤0.01% 2472
2021
Q3 		$657K Buy
11,772
+5,243
+80% +$258K ﹤0.01% 2373
2021
Q2 		$279K Hold
6,529
– – ﹤0.01% 2657
2021
Q1 		$273K Hold
6,529
– – ﹤0.01% 2504
2020
Q4 		$304K Hold
6,529
– – ﹤0.01% 2407
2020
Q3 		$277K Hold
6,529
– – ﹤0.01% 2329
2020
Q2 		$313K Buy
6,529
+128
+2% +$6.39K ﹤0.01% 2267
2020
Q1 		$294K Sell
6,401
-3,714
-37% -$186K ﹤0.01% 2159
2019
Q4 		$608K Buy
10,115
+3,414
+51% +$204K ﹤0.01% 2158
2019
Q3 		$379K Hold
6,701
– – ﹤0.01% 2380
2019
Q2 		$373K Hold
6,701
– – ﹤0.01% 2334
2019
Q1 		$338K Buy
6,701
+1,401
+26% +$62.3K ﹤0.01% 2265
2018
Q4 		$214K Hold
5,300
– – ﹤0.01% 2362
2018
Q3 		$367K Hold
5,300
– – ﹤0.01% 2209
2018
Q2 		$401K Buy
+5,300
New +$333K ﹤0.01% 2190
2016
Q4 		– Sell
-3,500
Closed -$245K – 2688
2016
Q3 		$245K Buy
+3,500
New +$194K ﹤0.01% 2366
2016
Q1 		– Sell
-3,900
Closed -$346K – 2672
2015
Q4 		$346K Hold
3,900
– – ﹤0.01% 2270
2015
Q3 		$289K Buy
3,900
+400
+11% +$33.3K ﹤0.01% 2307
2015
Q2 		$283K Buy
+3,500
New +$228K ﹤0.01% 2401

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS AM's EGRX Position: Q3 2023 in Review

UBS AM sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 7,255 shares — an estimated $206K sold.

UBS AM first reported a position in EGRX in Q2 2015 and held it in 25 quarters. The position peaked at $664K in Q1 2022. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • UBS AM reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 7,255 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $206K.
  • UBS AM first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 25 quarters.
  • UBS AM's Eagle Pharmaceuticals, Inc. position peaked at $664K in Q1 2022.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.